Use of the Hansen Medical System in Patients With Atrial Fibrillation (ARTISAN AF)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess the safety and performance of the Hansen Medical Sensei Robotic System and Artisan Catheter when used to robotically manipulate the Biosense ThermoCool ablation catheter for the treatment of atrial fibrillation (irregular heartbeats originating in the upper chambers of the heart). The Biosense ThermoCool catheter is FDA approved for use in ablation therapy. The Hansen Medical Robotic Sensei System and Artisan catheter is approved in Europe for use during ablation procedures. This system has been used to treat atrial fibrillation in over 1000 patients worldwide by navigating existing, approved ablation catheters. In the US the Hansen Sensei System with Artisan catheter has FDA clearance as a robotic delivery system to facilitate manipulation, positioning and control of catheters used to collect electrophysiological data within the heart atria (upper chambers or the heart) but has not been studied or approved in the US for use in ablation treatment This study is looking to show safety, compatibility and effectiveness when the Hansen system is used in conjunction with the ThermoCool ablation catheter in the treatment of atrial fibrillation. This will be done by to either treatment with manual delivery of the ThermoCool ablation catheter or treatment with robotic delivery of the of the ThermoCool ablation catheter.
| Condition | Intervention |
|---|---|
|
Paroxysmal Atrial Fibrillation |
Device: RF Ablation |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Prospective, Randomized Study of the Hansen System for Introducing and Positioning the Thermocool Catheter in Patients With Atrial Fibrillation |
- The absence of early onset (within 7 days of the ablation procedure) of all Serious Adverse Events as defined in the protocol. [ Time Frame: 0 - 7 days ] [ Designated as safety issue: Yes ]
- Freedom from symptomatic atrial fibrillation from days 91-365 (chronic procedural success). [ Time Frame: 91 - 365 days ] [ Designated as safety issue: No ]
- Absence of esophageal injury or pulmonary vein stenosis through day 365. [ Time Frame: 0 - 365 days ] [ Designated as safety issue: Yes ]
- Freedom from serious adverse events (SAEs) from day 8 through day 365. [ Time Frame: 8 - 365 days ] [ Designated as safety issue: Yes ]
- Acute pulmonary vein isolation of at least three out of four veins, as documented by testing entrance block, during the procedure. [ Time Frame: 0 days ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 300 |
| Study Start Date: | May 2010 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Robotic catheter manipulation for RF Ablation
Introduce and position ThermoCool remotely through the Artisan Control Catheter.
|
Device: RF Ablation
PV isolation is the required ablation procedure.
Other Names:
|
|
Active Comparator: Manual catheter manipulation for RF Ablation
Introduce and position the ThermoCool manually.
|
Device: RF Ablation
PV isolation is the required ablation procedure.
Other Names:
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with paroxysmal atrial fibrillation who have had two or more spontaneously terminating episodes of atrial fibrillation, that last longer than 30 seconds and shorter than 7 days, in the nine months prior to enrollment. At least one episode must be documented with EKG, TTM, Holter monitor, or telemetry.
- Failure of at least one Class I - IV anti-arrhythmic drug (AAD) for PAF as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AAD. AADs are defined in Appendix B.
- Signed informed consent.
- Age 18 years or older
- Able and willing to comply with all pre-, post-, and follow-up testing and requirements.
Exclusion Criteria:
- Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
- Previous ablation for atrial fibrillation.
- Atrial fibrillation episodes that last less than 7 days and are terminated by cardioversion.
- Previous valvular cardiac surgery procedure.
- Cardiac artery bypass graft procedure within the previous 180 days.
- Previous septal defect repair.
- Expecting cardiac transplantation or other cardiac surgery within the next 180 days.
- Coronary PTCA/stenting within the previous 180 days.
- Documented left atrial thrombus on ultrasound imaging (TEE).
- Documented history of a thrombo-embolic event within the previous year.
- Diagnosed atrial myxoma.
- Presence of an implanted ICD.
- Presence of permanent pacing leads.
- Significant restrictive, constrictive, or chronic obstructive pulmonary disease or any other disease or malfunction of the lungs or respiratory system with chronic symptoms.
- Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
- Women who are pregnant.
- Acute illness or active infection at time of index procedure documented by either pain, fever, drainage, positive culture and/or leukocytosis (WBC > 11.000 mm3) for which antibiotics have been or will be prescribed.
- Creatinine > 2.5 mg/dl (or > 221 µmol/L).
- Unstable angina.
- Myocardial infarction within the previous 60 days.
- Left ventricular ejection fraction less than 40%
- History of blood clotting or bleeding abnormalities.
- Contraindication to anticoagulation.
- Contraindication to computed tomography or magnetic resonance imaging procedures.
- Life expectancy less than 1 year.
- Enrollment in another investigational study.
- Uncontrolled heart failure (NYHA class III or IV heart failure).
- Presence of an intramural thrombus, tumor, or other abnormality that precludes catheter introduction or positioning.
- Presence of a condition that precludes vascular access.
- Left Atrial size ≥ 50mm.
- INR greater than 3.0 within 24 hours of procedure.
Contacts and Locations| United States, California | |
| Stanford Univeristy Medical Center | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Linda Norton, RN 650-725-5597 lnorton@stanfordmed.org | |
| Principal Investigator: Amin Al-Ahmad, MD | |
| United States, Minnesota | |
| Mayo Clinic | Recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: Kelly Wock 507-255-7456 wock.kelly@mayo.edu | |
| Principal Investigator: Douglas Packer, MD | |
| United States, New York | |
| Stony Brook Univeristy Medical Center | Recruiting |
| Stony Brook, New York, United States, 11794 | |
| Contact: Joyce Quick, PA 631-444-8485 Joyce.Quick@stonybrookmedicine.edu | |
| Principal Investigator: Eric Rashba, MD | |
| United States, North Carolina | |
| Duke University Health System | Recruiting |
| Durham, North Carolina, United States, 27710 | |
| Contact: Debbie Hickey 919-668-3524 deborah.hickey@duke.edu | |
| Principal Investigator: Patrick Hranitzky, MD | |
| United States, South Carolina | |
| Greenville Memorial Hospital | Recruiting |
| Greenville, South Carolina, United States, 29605 | |
| Contact: Erikia Channell 864-455-2288 echannell@ghs.org | |
| Contact: Maureen Coyne 864-455-7727 mcoyne@ghs.org | |
| Principal Investigator: Donald Rubenstein, MD | |
| Sub-Investigator: Joseph Manfredi, MD | |
| United States, Texas | |
| Texas Cardiac Arrhythmia Research Foundation (TCARF) | Recruiting |
| Austin, Texas, United States, 78705 | |
| Contact: Deb Cardinal 512-458-9410 dscardinal@austinheartbeat.com | |
| Principal Investigator: G. J. Gallinghouse, M.D. | |
| Houston Methodist | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Melinda Tindel 713-441-3248 MTindel@tmhs.org | |
| Principal Investigator: Miguel Valderrábano, MD | |
| United States, Virginia | |
| Univeristy of Virginia | Recruiting |
| Charlottesville, Virginia, United States, 22908 | |
| Contact: Mary Jane Strickland 434-982-6401 MJS7W@hscmail.mcc.virginia.edu | |
| Principal Investigator: J. Michael Mangrum, MD | |
| Principal Investigator: | Andrea Natale, M.D. | Texas Cardiac Arrhythmia Research Foundation |
| Study Director: | Dale Bergman | Hansen Medical, Inc. |
More Information
No publications provided
| Responsible Party: | Hansen Medical |
| ClinicalTrials.gov Identifier: | NCT01122173 History of Changes |
| Other Study ID Numbers: | HMP010 |
| Study First Received: | May 10, 2010 |
| Last Updated: | August 22, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Hansen Medical:
|
Atrial Fibrillation Robotic Control Remote Control |
Additional relevant MeSH terms:
|
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013